The tumor microenvironment (TME) - a heterogeneous combination of tumor-associated fibroblasts, immune and stromal cells, signaling factors, and extracellular matrix components surrounding a tumor site - is an integral component of both solid and hematological malignancies. Is it known that tumors can actively modify their surrounding environment to gain protection from the immune system and enhance proliferation, such as through subversion of systemic glucose metabolism or mitochondrial trafficking to the TME. Furthermore, the TME helps to maintain a pro-inflammatory microenvironment, can contribute to tumor progression and invasion, and can contribute to therapy resistance. TheTME is characterized by a dynamic topography and the ways in which tumor cells respond to microenvironment stimuli depend on which regions they interact with. Differences in hypoxic status, cytokine expression, and infiltrated immunological suppressive cells and effector cells can significantly impact tumor development and status.
Despite recent advances in our understanding of the TME and its role in shaping hematologic malignancies, the interplay between tumors and the TME is complex and is not fully understood. This Research Topic aims to provide insights into the impact of TME heterogeneity on hematological malignancy onset and development.
We welcome Original Research Articles and Review Articles focused on, but not limited to:
- New discoveries on the origin of spatial and temporal heterogeneity of the hematological tumor microenvironment
- New therapeutic strategies to overcome microenvironment heterogeneity-related resistance to therapies
- Molecular mechanisms of microenvironment heterogeneity-related therapy resistance
- How the heterogeneous microenvironment components determine tumor behavior and pathogenesis
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
The tumor microenvironment (TME) - a heterogeneous combination of tumor-associated fibroblasts, immune and stromal cells, signaling factors, and extracellular matrix components surrounding a tumor site - is an integral component of both solid and hematological malignancies. Is it known that tumors can actively modify their surrounding environment to gain protection from the immune system and enhance proliferation, such as through subversion of systemic glucose metabolism or mitochondrial trafficking to the TME. Furthermore, the TME helps to maintain a pro-inflammatory microenvironment, can contribute to tumor progression and invasion, and can contribute to therapy resistance. TheTME is characterized by a dynamic topography and the ways in which tumor cells respond to microenvironment stimuli depend on which regions they interact with. Differences in hypoxic status, cytokine expression, and infiltrated immunological suppressive cells and effector cells can significantly impact tumor development and status.
Despite recent advances in our understanding of the TME and its role in shaping hematologic malignancies, the interplay between tumors and the TME is complex and is not fully understood. This Research Topic aims to provide insights into the impact of TME heterogeneity on hematological malignancy onset and development.
We welcome Original Research Articles and Review Articles focused on, but not limited to:
- New discoveries on the origin of spatial and temporal heterogeneity of the hematological tumor microenvironment
- New therapeutic strategies to overcome microenvironment heterogeneity-related resistance to therapies
- Molecular mechanisms of microenvironment heterogeneity-related therapy resistance
- How the heterogeneous microenvironment components determine tumor behavior and pathogenesis
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
